ASTRAZENECA PHARMACEUTICALS, LP — FDA ORIG Approval for ETCAMAH (Not disclosed in the FDA record.)

Key facts

What was approved

FDA's record shows ASTRAZENECA PHARMACEUTICALS, LP as the sponsor of ETCAMAH, with the generic name recorded as unspecified and dosage form TABLET. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. This specific application is submission type ORIG (submission number 1) under application number NDA220359, with a submission status date of 20260904. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Regulatory context

This application was reviewed under FDA's ORIG submission pathway. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

ASTRAZENECA PHARMACEUTICALS, LP’s FDA history

Argus HQ has recorded 1 total FDA action tied to ASTRAZENECA PHARMACEUTICALS, LP: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.

Frequently asked questions

Is this product available now?

FDA's record lists a submission status date of 20260904. Availability, pricing, and distribution details beyond the submission status date are Not disclosed in the FDA record. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Does ASTRAZENECA PHARMACEUTICALS, LP have other FDA approval records?

This is the only FDA action Argus HQ has on file for ASTRAZENECA PHARMACEUTICALS, LP so far. Argus ingests new FDA records daily.

What is the FDA application number for this submission?

FDA application number NDA220359, submission 1.

What review priority did FDA assign?

FDA designated this submission as: STANDARD.

Related enforcement actions

• Approval (recent): LUPIN — ANDA approval: MODAFINIL (unspecified) →
• Approval (recent): BPI LABS — ANDA approval: TESTOSTERONE CYPIONATE (unspecified) →
• Approval (recent): ZHEJIANG JUTAI PHARM — ANDA approval: BRIVARACETAM (unspecified) →
• Approval (recent): MSN — ANDA approval: TAPENTADOL HYDROCHLORIDE (unspecified) →
• Approval (recent): HANDA ONCOLOGY, LLC — NDA approval: Unspecified (unspecified) →
• Approval (recent): AUROBINDO PHARMA LTD — ANDA approval: SACUBITRIL AND VALSARTAN (unspecified) →
• Approval (recent): IONIS PHARMS INC — NDA approval: ZANVASTRO (unspecified) →
• Approval (recent): PRECISION DOSE INC — ANDA approval: ALENDRONATE SODIUM (unspecified) →